Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204153 | 0.80 | KDM4E (0.44) | KDM4EMMP14NR4A2CASP6PRMT5 | |
| SCHEMBL22587674 | 0.77 | KDM4E (0.42) | KDM4EMMP14NR4A2CASP6PRMT5 | |
| SCHEMBL22595963 | 0.77 | PRMT5 (0.47) | KDM4ECASP6PRMT5HSP90AA1HSP90AB1 | |
| SCHEMBL27993579 | 0.77 | KDM4E (0.42) | KDM4EG6PDMMP14NR4A2PRMT5 | |
| SCHEMBL2706312 | 0.77 | HSP90AA1 (0.58) | KDM4EMMP14NR4A2CASP6PRMT5 | |
| SCHEMBL31330029 | 0.77 | MEN1 (0.44) | KDM4EMMP14NR4A2CASP6PRMT5 | |
| SCHEMBL22595525 | 0.73 | PRMT5 (0.40) | KDM4EG6PDMMP14CASP6PRMT5 | |
| SCHEMBL29288471 | 0.73 | PRMT5 (0.40) | KDM4EG6PDCASP6PRMT5HSP90AA1 | |
| SCHEMBL6646968 | 0.73 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2TDP1HPGD | |
| SCHEMBL15273710 | 0.73 | KMT2A (0.46) | KDM4EHSP90AA1IDO1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3584237-B1 | ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-12-09 | — | — | EP | disclosed |
| EP-2486009-B1 | 2H-PYRROL-5-AMINE DERIVATIVES AS ALPHA ADRENERGIC RECEPTOR MODULATORS | ALLERGAN INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-20160045489-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2016-02-18 | — | — | US | disclosed |
| US-9199989-B2 | N—(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors | ALLERGAN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140329852-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2014-11-06 | — | — | US | disclosed |
| US-8815861-B2 | N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors | ALLERGAN, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| EP-2736902-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | Allergan, Inc. (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20130029994-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN, INC. | 2013-01-31 | — | — | US | disclosed |
| WO-2013016178-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ALLERGAN, INC. (US) | 2013-01-31 | — | — | WO | disclosed |
| EP-1789042-B1 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2012-05-02 | — | — | EP | disclosed |
| US-7579359-B2 | 1-alkoxy 1H-imidazo ring systems and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2009-08-25 | — | — | US | disclosed |
| EP-1789042-A4 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES CO (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090005376-A1 | imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2009-01-01 | — | — | US | disclosed |
| EP-1968587-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS | Coley Pharmaceutical, Inc. (US) | 2008-09-17 | — | — | EP | disclosed |
| EP-1937683-A1 | METHOD FOR 1H-IMIDAZOÝ4,5-c¨PYRIDINES AND ANALOGS THEREOF | Coley Pharmaceutical Group, Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007106852-A2 | SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2007075468-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1789042-A2 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007035935-A1 | METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2006028962-A2 | 1-ALKOXY 1H-IMIDAZO RING SYSTEMS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160045489-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ADRB2, ADRA2C, ADRA2A | KDM4E 4038/4885G6PD 3081/4885MMP14 4884/4885 |
| US-20130029994-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ADRB2, ADRA2C, ADRA2A | KDM4E 4038/4885G6PD 3081/4885MMP14 4884/4885 |
| US-20140329852-A1 | N-(IMIDAZOLIDIN-2-YLIDENE)QUINOLINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS | ADRB2, ADRA2C, ADRA2A | KDM4E 4038/4885G6PD 3081/4885MMP14 4884/4885 |
| US-20090005376-A1 | imidazonaphthyridines, imidazopyridines, imidazoquinolines, and imidazote-trahydroquinolines; immunomodulators for inducing cytokine biosynthesis; for treatment of viral and neoplastic diseases | IL2, IL4, IRF3 | KDM4E 2441/4885G6PD 1923/4885MMP14 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.